vesnarinone

出典: meddic

ベスナリノン

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2014/01/30 18:16:50」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

英文文献

  • Visualization and dynamics of multidimensional health-related quality-of-life-adjusted overall survival: a new analytic approach.
  • Andrei AC, Grady KL.Author information Bluhm Carrdiovascular Institute, Northwestern University, 676 N St Clair St., Suite 1700, Chicago, IL, USA, aandrei@nmh.org.AbstractBACKGROUND: Vesnarinone Trial (VesT) was a three-armed, placebo-controlled, randomized clinical trial designed to study the effects of 30 mg or 60 mg/day vesnarinone. Certain contradictory results involving patient health-related quality-of-life (HRQOL) and overall survival (OS) have made a definitive and unified conclusion difficult.
  • Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation.Qual Life Res.2014 Jan 7. [Epub ahead of print]
  • BACKGROUND: Vesnarinone Trial (VesT) was a three-armed, placebo-controlled, randomized clinical trial designed to study the effects of 30 mg or 60 mg/day vesnarinone. Certain contradictory results involving patient health-related quality-of-life (HRQOL) and overall survival (OS) have made a definiti
  • PMID 24395525
  • Vesnarinone suppresses TNFα mRNA expression by inhibiting valosin-containing protein.
  • Hotta K, Nashimoto A, Yasumura E, Suzuki M, Azuma M, Iizumi Y, Shima D, Nabeshima R, Hiramoto M, Okada A, Sakata-Sogawa K, Tokunaga M, Ito T, Ando H, Sakamoto S, Kabe Y, Aizawa S, Imai T, Yamaguchi Y, Watanabe H, Handa H.Author information Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Yokohama, Kanagawa, Japan.AbstractVesnarinone is a synthetic quinolinone derivative used in the treatment of cardiac failure and cancer. It is also known to cause agranulocytosis as a side effect, which restricts its use, although the mechanism underlying agranulocytosis is not well understood. Here, we show that vesnarinone binds to valosin-containing protein (VCP), which interacts with polyubiquitinated proteins and is essential for the degradation of IκBα to activate nuclear factor (NF)κB. We show that vesnarinone impairs the degradation of IκBα, and that the impairment of the degradation of IκBα is the result of the inhibition of the interaction between VCP and the 26S proteasome by vesnarinone. These results suggest that vesnarinone suppresses NFκB activation by inhibiting the VCP-dependent degradation of polyubiquitinated IκBα, resulting in the suppression of tumor necrosis factor-α mRNA expression.
  • Molecular pharmacology.Mol Pharmacol.2013 May;83(5):930-8. doi: 10.1124/mol.112.081935. Epub 2013 Feb 7.
  • Vesnarinone is a synthetic quinolinone derivative used in the treatment of cardiac failure and cancer. It is also known to cause agranulocytosis as a side effect, which restricts its use, although the mechanism underlying agranulocytosis is not well understood. Here, we show that vesnarinone binds t
  • PMID 23393163
  • New predictive models of heart failure mortality using time-series measurements and ensemble models.
  • Subramanian D, Subramanian V, Deswal A, Mann DL.Author information Department of Computer Science, Rice University, Houston, TX 77005, USA. devika@rice.eduAbstractBACKGROUND: Morbidity and mortality rates associated with heart failure remain high. A wide variety of demographic and clinical factors as well as biomarkers are associated with increased mortality rates. Despite this, most multivariate predictive models for heart failure mortality have predictive accuracies characterized by a C-statistic (area under the receiver operating curve) of ≈0.74.
  • Circulation. Heart failure.Circ Heart Fail.2011 Jul;4(4):456-62. doi: 10.1161/CIRCHEARTFAILURE.110.958496. Epub 2011 May 11.
  • BACKGROUND: Morbidity and mortality rates associated with heart failure remain high. A wide variety of demographic and clinical factors as well as biomarkers are associated with increased mortality rates. Despite this, most multivariate predictive models for heart failure mortality have predictive a
  • PMID 21562057

和文文献

  • Vesnarinone downregulates CXCR4 expression via upregulation of Kruppel-like factor 2 in oral cancer cells
  • Uchida Daisuke,Onoue Tomitaro,Begum Nasima-Mila,Kuribayashi Nobuyuki,Tomizuka Yoshifumi,Tamatani Tetsuya,Nagai Hirokazu,Miyamoto Youji
  • MOLECULAR CANCER 8, 2009
  • NAID 120004710201
  • ケモカインレセプターCXCR4を標的とした口腔癌に対するリンパ節転移抑制療法の開発
  • 富塚 佳史
  • 四国歯学会雑誌 20(1), 155-175, 2007-06
  • … Consequently, vesnarinone, a newly identified chemotherapeutic agent, trascriptionally downregulated CXCR4. … Vesnarinone inhibited the cell migration induced by SDF-1 and lymph node metastasis of cells in the orthotopic inoculation model. … By using several deletion constructs against CXCR4 promoters, the minimal vesnarinone-responsive element in the CXCR4 promoter region at -300 to -167 relative to the transcription start site was identified. …
  • NAID 110006561013

関連リンク

vesnarinone Cardiology A quinolinone with a narrow therapeutic range; withdrawn from the market. See Flosequinan. ... The chemical synthesis and the pharmacologica [studies of tetrahydroquinoline derivatives such as Sumanirole ...
Vesnarinone (INN) is a cardiotonic agent. A mixed phosphodiesterase 3 inhibitor and ion-channel modifier that has modest, dose-dependent, positive inotropic activity, but minimal negative chronotropic activity. Vesnarinone improves ...

関連画像


押しても画像が表示されない場合はサーバが混雑しています。2週間ほどあけて、再度押下してください。


★リンクテーブル★
リンク元ベスナリノン

ベスナリノン」

  [★]

vesnarinone
アーキンZ





★コメント★

[メモ入力エリア]
※コメント5000文字まで
ニックネーム:
コメント:




表示
個人用ツール


  meddic.jp

リンク
連絡